Search

 

Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.

New Molecule

4 New

New Formulation

3 New

New Brand

30 New

Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in